All Migraine Articles

By affecting chaotic (nonlinear) controls, new therapies may be employed that use less drug in the migraine cascade than is currently required.
For many patients, refractory chronic migraines can be disabling and debilitating. Treating these patients may require a combination of therapeutic approaches.
Stimulants may be beneficial for chronic migraine patients presenting with various comorbidities such as attention deficit hyperactivity disorder (ADHD), depression and fatigue.
Study results for a group of difficult-to-treat migraineurs provide a basis for determining efficacy and guidelines for the use of long-term opioids in this population.
This retrospective case series study revealed that Hackett-Hemwall dextrose prolotherapy appears to provide an effective, long-lasting treatment for recurring tension and migraine headache pain and their associated symptoms.
With a higher than normal prevalence of moderate or severe personality disorder in patients who have migraines, recognizing the disorder allows alteration of both goals and approach.
Outpatient intravenous ketamine treatment of CRPS-Type 1 simultaneously eradicated post-concussional migraine in patient.
An outpatient clinic can provide an effective variety of IV treatments—individually or in combination— for definitive control of pain for a variety of pain disorders, including migraines and fibromyalgia.
The number one drug used by neurologists for migraine and daily headache, topirimate, is still reluctantly used by primary care physicians. This article is an attempt to demystify a very effective medication in the physician's migraine armentarium.
Article provides an overview of treatment-resistant Migraines. Alternate strategies may be required for overcoming the treatment resistance of certain types of migraines.
Discussion of triptan options in the treatment of migraines. Reviews available migraine medications.
An overview of the efficacy of several triptan agents in menstrually-related migraine (MM), as well as of other treatment modalities that are commonly used in the treatment of MM.
Our patient Heather (not her real name) initially came in at age 24 and we chronicled her history and early treatment.1 In summary, Heather has moderate daily headache (CDH), with migraine 6 times per month. She also suffers from anxiety and depression (the mild end of the bipolar spectrum). Heather has irritable bowel syndrome (IBS; primarily diarrhea) plus neck pain.
Memantine has only recently been introduced in the U.S. for dementing disorders, although it has been used in Europe for some time. It blocks N-methyl-D-aspartate (NMDA) glutamate receptors that are thought to be intrinsic to pain transmission, windup, long-term potentiation and central sensitization.
Read about this case: Heather is a 30-year-old hairdresser in a salon. Her work can be very physical, and her life has not been easy. Heather is currently on 50 mg of topiramate and 25 mg of quetiapine to prevent headaches but cannot tolerate higher doses of either medication.